CTLA4 and cancer: In many cancers, immunoregulatory mechanisms have been proved to hamper antitumor immunotherapy, including ligand-mediated engagement of IRs on effector cells, such as CTLA4, and induction of immunosuppressive cell subsets, such as Tregs or MDSCs (78–80).